Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Mucositis 4Hematologic Neoplasms 3Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Thrombocytopenia 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neutropenia 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphopenia 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Graft vs Host Disease 1Cytopenia 1Anemia 1

Interventions

eltrombopag 5romiplostim 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2oprelvekin 1lusutrombopag 1avatrombopag 1angiotensin I (1-7) 1Interleukin-11 1Injections 1Gemcitabine 1Daunorubicin 1Cytarabine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thrombocytopenia × angiotensin I (1-7) × Clear all
NCT00771810 2017-11-13

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

Tarix Pharmaceuticals

Phase 2 Completed
34 enrolled 19 charts
Classical hematologyGynecologic

Cytopenia, Anemia, Lymphopenia, Neutropenia, Ovarian Neoplasms, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡